Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …

Pancreatic cancer (PC) is one of the most lethal malignancies. Recent studies indicate that
patients with incidentally diagnosed PC have better prognosis than those with symptoms …

Pancreatic ductal adenocarcinoma (PDAC) tumor growth is enhanced by tumor-associated
macrophages (TAMs), yet the mechanisms by which tumor cells and TAMs communicate are …

Platelets have been recognized as key players in hemostasis, thrombosis, and cancer.
Preclinical and clinical researches evidenced that tumorigenesis and metastasis can be …

The majority of cancer patients respond poorly to either vaccine or checkpoint blockade, and
even to the combination of both. They are often resistant to high doses of radiation therapy …

Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an
average 5-year survival rate of 9%(Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019; …

Morphological heterogeneity is a common finding in pancreatic ductal adenocarcinoma.
Inter-and intra-tumour heterogeneity relates not only to the microscopic appearances of the …

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second
leading cause of cancer related mortality in the United States in 2030, with a 5-year overall …

ABSTRACT A patient‐derived xenograft (PDX) approach, which relies on direct
transplantation of tumor specimens into an immunocompromised animal, is a commonly …

Pancreatic cancer is a cruel, progressive disease that is highly metastatic and barely
treatable, a situation that is devastating for patients, family members, oncologists, clinicians …